Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Bosch, Ronald J ^a   Pollard, Richard B ^b   Landay, Alan ^c   Aga, Evgenia ^a   Fox, Lawrence ^d   Mitsuyasu, Ronald ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS EFAVIRENZ PLUS NELFINAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE PLUS INDINAVIR PLUS STAVUDINE; DIDANOSINE PLUS NELFINAVIR PLUS STAVUDINE; INDINAVIR; INDINAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; INTERLEUKIN 2; LAMIVUDINE; LAMIVUDINE PLUS NELFINAVIR PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NELFINAVIR PLUS STAVUDINE; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 77955214080     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-30     Document Type: Article

References (6)

1. Pett SL, Emery S. Immunomodulators as adjunctive therapy for HIV-1 infection. J Clin Virol 2001, 22:289-295. 10.1016/S1386-6532(01)00201-3, 11564594.
2. Sereti I, Anthony KB, Martinez-Wilson H, et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004, 104:775-780. 10.1182/blood-2003-12-4355, 15090457.
3. Kovacs JA, Lempicki RA, Sidorov IA, et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005, 115:2139-2148. 10.1172/JCI23196, 1174914, 16025158.
4. Mitsuyasu R, Gelman R, Cherng DW, et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med 2007, 167:597-605. 10.1001/archinte.167.6.597, 17389292.
5. Abrams D, Lévy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361:1548-1559. 10.1056/NEJMoa0903175, 19828532.
6. De Paoli P, Bortolin MT, Zanussi S, et al. Changes in thymic function in HIV-positive patients treated with highly active antiretroviral therapy and interleukin-2. Clin Exp Immunol 2001, 125:440-446. 10.1046/j.1365-2249.2001.01615.x, 1906157, 11531952.